If you're responsible for getting a medical device through FDA clearance—or for designing one with a robust cybersecurity posture—this guide is for you.
Quality and Regulatory Affairs teams need clarity on what FDA actually requires versus what's mentioned in the myriad of guidance documents. You're accountable for the success of submissions, and cybersecurity deficiencies are increasingly common reasons for rejection.
R&D and Design Engineering teams need to know what to build into the device—and when. Retrofitting cybersecurity controls after design freeze is expensive and delays timelines.
The challenge is that FDA's cybersecurity guidance spans multiple documents, references numerous standards, and uses terminology that can obscure rather than clarify. This guide cuts through that complexity.
The checkbox problem: Design controls often become an afterthought—a paperwork exercise to complete before submission rather than tools that shape the design. This approach leads to predictable consequences:
Quality and Regulatory Affairs teams struggle to move engineering beyond a "paperwork" mindset to achieve true compliance.
R&D and Design Engineering teams need design controls to help catch problems early and clarify requirements rather than slowing them down.
Project Managers must plan these activities into schedules so milestones become meaningful decision points.
Are your mandatory Design Reviews catching problems or just checking boxes? Design Reviews (DR) are supposed to catch problems early—when changes are cheap. But in practice, many reviews become rubber stamps without pressure-testing the device design.
The common failure pattern we see includes:
The result is that problems that should have been caught at a preliminary DR surface during Design Verification testing, or worse, in the field. Our scorecard provides an objective way to assess whether your DRs are actually working.
The robustness problem: Your device works perfectly in the lab, but failures start to appear in the field. These aren't manufacturing defects; they are robustness failures where the design didn't account for real-world variation.
The team likely designed for ideal conditions without systematically thinking through noise factors in actual use. Parameter Diagrams (P-Diagrams) solve this by forcing disciplined thinking about variation before design freeze.
Design Engineers need this structured method to identify failure modes and translate them into robust design requirements.
Quality Engineers want better traceability from user needs through Design Inputs to DFMEA, without gaps.
Project Managers must ensure robustness analysis happens early in development, not as an afterthought.
Cybersecurity testing is critical, but it should never be your only line of defense. Many Medical Device Manufacturers (MDM) rely solely on late-stage penetration testing. However, a single pass doesn't mean the device is secure; it just means testers didn't find a way in this time.
Robust security is built in layers through:
Quality and Regulatory Affairs teams need to understand what testing evidence the FDA expects and how standards support submissions.
Software and Systems Engineering teams require clarity on test types and when to apply them during execution.
R&D Leadership must plan development timelines to include cybersecurity activities early.
Why cybersecurity labeling matters: Your device may have robust controls, but if your labeling doesn't communicate them to users, FDA reviewers will find it as a gap. Under Section 524B of the FD&C Act, incomplete labeling can result in RTA decisions or delayed clearance.
This guide breaks down exactly what FDA expects, including:
Regulatory Affairs teams preparing 510(k), De Novo, or PMA submissions need to ensure documentation is complete before submission.
Technical Writers developing IFUs and user manuals need specific requirements to write against.
Engineering teams must know what architecture diagrams and SBOM details to provide to the labeling team.
